This process strengthens the immune response against neoplasms and specifically targets immune checkpoint proteins such as PD-1 and its ligands (PD-L1 and PD-L2), as well as other targets such as CTLA-4, to enhance the anti-tumor effects of T cells, preventing them from attacking cancer cells [72]. This evidence concerns the gene PDCD1LG2 and neoplasm.